NCT06018558: Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 60 taking part
- Started
- 27 Oct 2023
- Primary completion
- 3 Feb 2026
- Arms
- Phase1 Dose Escalation- Low Dose (2.5×10E10 vg/mL):, Phase1 Dose Escalation- Medium Dose (5×10E10 vg/mL):, Phase1 Dose Escalation- High Dose (1.5×10E11 vg/mL):, Phase 2 Dose Expansion: Maximum tolerated dose (MTD) from Phase 1-Randomized Arm, Phase 2 Dose Expansion: Lower Dose from Phase 1-Randomized Arm
- Results
- None posted
- 30 Aug 2023: Trial registered
- 27 Oct 2023: Trial started